"Anti-Arrhythmia Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.
| Descriptor ID |
D000889
|
| MeSH Number(s) |
D27.505.954.411.097
|
| Concept/Terms |
Anti-Arrhythmia Agents- Anti-Arrhythmia Agents
- Agents, Anti-Arrhythmia
- Anti Arrhythmia Agents
- Antiarrhythmic Drugs
- Drugs, Antiarrhythmic
- Antiarrhythmia Agents
- Agents, Antiarrhythmia
- Antiarrhythmia Drugs
- Drugs, Antiarrhythmia
- Anti-Arrhythmia Drugs
- Anti Arrhythmia Drugs
- Drugs, Anti-Arrhythmia
- Anti-Arrhythmics
- Anti Arrhythmics
Cardiac Depressants- Cardiac Depressants
- Depressants, Cardiac
- Myocardial Depressants
- Depressants, Myocardial
|
Below are MeSH descriptors whose meaning is more general than "Anti-Arrhythmia Agents".
Below are MeSH descriptors whose meaning is more specific than "Anti-Arrhythmia Agents".
This graph shows the total number of publications written about "Anti-Arrhythmia Agents" by people in this website by year, and whether "Anti-Arrhythmia Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 3 | 2 | 5 |
| 1997 | 8 | 2 | 10 |
| 1998 | 7 | 5 | 12 |
| 1999 | 6 | 2 | 8 |
| 2000 | 9 | 6 | 15 |
| 2001 | 2 | 4 | 6 |
| 2002 | 5 | 2 | 7 |
| 2003 | 5 | 4 | 9 |
| 2004 | 11 | 6 | 17 |
| 2005 | 16 | 7 | 23 |
| 2006 | 5 | 5 | 10 |
| 2007 | 10 | 5 | 15 |
| 2008 | 12 | 9 | 21 |
| 2009 | 16 | 6 | 22 |
| 2010 | 11 | 13 | 24 |
| 2011 | 13 | 9 | 22 |
| 2012 | 6 | 7 | 13 |
| 2013 | 4 | 9 | 13 |
| 2014 | 7 | 9 | 16 |
| 2015 | 7 | 3 | 10 |
| 2016 | 12 | 5 | 17 |
| 2017 | 5 | 2 | 7 |
| 2018 | 3 | 4 | 7 |
| 2019 | 6 | 5 | 11 |
| 2020 | 8 | 6 | 14 |
| 2021 | 0 | 4 | 4 |
| 2022 | 0 | 13 | 13 |
| 2023 | 3 | 13 | 16 |
| 2024 | 6 | 0 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Anti-Arrhythmia Agents" by people in Profiles.
-
Saksena S, Slee A, Merino JL, Goette A, Boriani G, Kowey PR, Piccini JP, Reiffel JA, Blomstr?m-Lundqvist C, Camm AJ. An international physician survey of current ablation practices in atrial fibrillation: An AIM-AF substudy. Heart Rhythm. 2025 Sep; 22(9):2174-2182.
-
Burashnikov A, Antzelevitch C. The Efficacy of I Na Block to Cardiovert Atrial Fibrillation Is Enhanced by Inhibition of I K1. J Cardiovasc Pharmacol. 2024 Oct 01; 84(4):434-439.
-
Frankel E, Ho R. Management of Ventricular Arrhythmias in Heart Failure: Can Less Be More? Curr Cardiol Rep. 2024 Oct; 26(10):1097-1103.
-
Duan HY, Barajas-Martinez H, Antzelevitch C, Hu D. The potential anti-arrhythmic effect of SGLT2 inhibitors. Cardiovasc Diabetol. 2024 07 15; 23(1):252.
-
Ruskin JN, Camm AJ, Dufton C, Woite-Silva AC, Tuininga Y, Badings E, De Jong JSSG, Oosterhof T, Aksoy I, Kuijper AFM, Van Gelder IC, van Dijk V, Nuyens D, Schellings D, Lee MY, Kowey PR, Crijns HJGM, Maupas J, Belardinelli L. Orally Inhaled Flecainide for Conversion of Atrial Fibrillation to Sinus Rhythm: INSTANT Phase 2 Trial. JACC Clin Electrophysiol. 2024 Jun; 10(6):1021-1033.
-
Kowey PR, Naccarelli GV. Antiarrhythmic Drug Therapy: Where Do We Go From Here? Circulation. 2024 03 12; 149(11):801-803.
-
Burashnikov A, Di Diego JM, Patocskai B, Echt DS, Belardinelli L, Antzelevitch C. Effect of Flecainide and Ibutilide Alone and in Combination to Terminate and Prevent Recurrence of Atrial Fibrillation. Circ Arrhythm Electrophysiol. 2024 01; 17(1):e012454.
-
Ullah W, Johnson D, Nair AS, Dikdan SJ, Frankel E, Humayun W, Pavri BB, Frisch D. Ablation Versus Antiarrhythmic Drugs as First-Line Therapy for Treatment-Naive Atrial Fibrillation: A Systematic Review and Meta-Analysis. Am J Cardiol. 2024 02 15; 213:63-68.
-
Olleik F, Kamareddine MH, Spears J, Tse G, Liu T, Yan GX. Mexiletine: Antiarrhythmic mechanisms, emerging clinical applications and mortality. Pacing Clin Electrophysiol. 2023 11; 46(11):1348-1356.
-
Kantharia BK, Shah AN. Are antiarrhythmic agents indicated in premature ventricular complex-induced cardiomyopathy and when? J Cardiovasc Electrophysiol. 2024 Mar; 35(3):574-582.